cloud dx stock

Cloud DX Reports Fiscal Second Quarter Results

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), (the "Company") a leading North American provider of virtual care and remote patient monitoring solutions today reports results for the second quarter of fiscal 2021

In addition, the Company will be hosting Its second quarter investor update and earnings call tomorrow, August 17, 2021, at 1:30pm EST. Robert Kaul, Founder and CEO, will be commenting on the Company's earnings and reviewing the most recent contract developments in the second quarter. To register please use the link below:

Click Here to Register for the Earnings Call

Key Developments:

  • Subscription revenue increased 39% YTD (3 months - increase of 90%);
  • Total revenue increased 8% YTD (3 months- decrease of 40%) despite a significant one-time hardware deployment in the previous year;
  • Gross profit increased 184% YTD (3 months - 66%)
  • New partnerships YTD in the quarter resulted in YTD access to 27,600 additional patients (3 months - 25,100)
  • Inclusion of one-time costs attributed to the Qualifying Transaction impacted expenses;
    • 115% increase in operating expenses
    • 149% decrease in adjusted EBITDA

Second Quarter Financial Highlights

Year to Date Financial Highlights

Second Quarter Revenue and Gross Profit
In the 3 months ended June 30, 2021 subscription revenue has Increased 90%. Product and professional services revenue is expected to be 'lumpy' in the early stages of growth. Specifically, in 2020 a large Connected Health Kit deployment for an academic study generated an unusual concentration of hardware revenue that has not occurred in 2021. Product revenue attracts a lower gross margin to subscription and professional fees.

Year to Date Revenue and Gross Profit
In the 6 months ended June 30, 2021 subscription revenue Increased 38.6%. Similar to the three month period, product and professional services revenue is expected to be "lumpy" in the early stages of growth. As noted above, in 2020 a large project-based order of Connected Health Kits had no comparison to date in 2021. With a lower proportion of product sales, gross margins increased.

Second Quarter Expenses
In the 3 months ended June 30, 2021 operating expenses increased 115% predominantly as a result of the non-cash stock based compensation expense that was impacted by the requirement to revalue employee stock-based compensation granted at the time of the Qualifying Transaction after prior grants were cancelled. Headcount increased by 26FTE's between June 30, 2020 and June 30, 2021 resulting in an 86.7% increase in the three month salaries and wages spend. Sales, General & Administrative expenses increased $296,447 or 243% as the company continued its efforts to scale.

Year to Date Expenses
In the 6 months ended June 30, 2021, operating expenses increased 115% predominantly as a result of certain cash and non-cash expenditures associated with the RTO; Professional fees were 199% higher due to costs attributable to this transaction; the non-cash stock based compensation expense was impacted by the requirement to revalue employee stock-based compensation granted at the time of the Qualifying Transaction after prior grants were cancelled. Headcount increased by 26 FTEs between June 30, 2020 and June 30, 2021 resulting in a 100% increase In salaries and wages. Sales, General & Administrative expenses Increased $396,347 or 188% as the company continued Its efforts to scale and office expenses increased $57,245 or 24% as a result of the expanded space leased in Kitchener, Ontario.

ACCESS TO PATIENTS
Through continually partnering with healthcare providers, Cloud DX has access to patients suited to its remote patient monitoring products as follows:

Number of patients as at January 1, 2021

3,700

Additional patients in Q1, 2021

2,500

Additional patients in Q2, 2021

25,100

Number of patients as at June 30, 2021

31,300

As of the date of this report and largely due to the recent partnership with Dagamma eCommerce Systems Inc., Cloud DX now has access to in excess of 100,000 patients.

About Cloud DX
Accelerating virtual healthcare's future, Cloud DX is making healthcare better for everyone. The company's Connected Health remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable ageing in place and deliver hospital-quality post-surgical care. Providers partnering with Cloud DX achieve better healthcare and patient outcomes, reduce the need for hospitalization/re-hospitalization and reduce the costs of healthcare delivery through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist and one of "Canada's Ten Most Prominent Telehealth Providers."

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cloud DX Investor Site: https://ir.clouddx.com/overview/default.aspx

Social Links
Twitter: https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries, please contact:
Ellyn Winters-Robinson
Ignition Communications (PR for Cloud DX)
519-574-2196
ellyn@ignition.ca

For investor inquiries, please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE: Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/660021/Cloud-DX-Reports-Fiscal-Second-Quarter-Results

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×